단백질 바이오마커 면역분석법 시장 규모, 점유율 및 동향 분석 보고서 : 제품별, 기술별, 임상 용도별, 검체별, 최종 용도별, 지역별 및 부문별 전망(2026-2033년)

Protein Biomarker Immunoassay Market Summary

The global protein biomarker immunoassay market size was valued at USD 6.8 billion in 2025 and is projected to grow from USD 7.2 billion in 2026 to USD 11.7 billion by 2033, at a CAGR of 7.1% from 2026 to 2033. North America dominated the market, accounting for the largest revenue share of 37.3% in 2025. Market growth is primarily driven by the growing adoption of blood-based protein biomarker testing for early disease detection, patient stratification, treatment monitoring, and assessment of disease progression across multiple clinical applications.

Blood-based immunoassays are increasingly preferred owing to their minimally invasive nature, established clinical laboratory workflows, and ability to measure disease-associated proteins from serum, plasma, and whole-blood samples.

Global Protein Biomarker Immunoassay Market Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the protein biomarker immunoassay market report based on product, technology, clinical application, sample, end use, and region:

• Product Outlook (Revenue, USD Billion, 2021 - 2033)
• Reagents & Consumables
• Instruments
• Software & Services
• Technology Outlook (Revenue, USD Billion, 2021 - 2033)
• Chemiluminescence Immunoassay
• ELISA
• Fluorescence Immunoassay
• Immunoturbidimetry & Nephelometry
• Lateral Flow Immunoassay
• Multiplex Immunoassay
• Digital Immunoassay
• Others
• Clinical Application Outlook (Revenue, USD Billion, 2021 - 2033)
• Cardiology
• Oncology
• Infectious Disease & Inflammation
• Neurology
• Endocrine & Metabolic Disorders
• Women's Health & Reproductive Disorders
• Autoimmune & Allergy Disorders
• Renal Disorders
• Others
• Sample Outlook (Revenue, USD Billion, 2021 - 2033)
• Serum
• Plasma
• Whole Blood
• Urine
• Cerebrospinal Fluid
• Saliva
• Others
• End Use Outlook (Revenue, USD Billion, 2021 - 2033)
• Hospitals & Clinics
• Diagnostic Laboratories
• Academic Medical Centers
• Specialty Diagnostic Centers
• Others
• Regional Outlook (Revenue, USD Billion, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Norway
  • Denmark
  • Sweden
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Market Definitions
  • 1.2.1. Product Segment
  • 1.2.2. Technology Segment
  • 1.2.3. Clinical Application Segment
  • 1.2.4. Sample Segment
  • 1.2.5. End User Segment
• 1.3. Information analysis
  • 1.3.1. Market formulation & data visualization
• 1.4. Data validation & publishing
• 1.5. Information Procurement
  • 1.5.1. Primary Infectious Disease Diagnostics
• 1.6. Information or Data Analysis
• 1.7. Market Formulation & Validation
• 1.8. Market Model
• 1.9. Total Market: CAGR Calculation
• 1.10. Objectives
  • 1.10.1. Objective 1
  • 1.10.2. Objective 2

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Snapshot
• 2.3. Competitive Insights Landscape

Chapter 3. Global Protein Biomarker Immunoassay Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook.
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Growing Adoption of Blood-Based Protein Biomarker Testing
    • 3.2.1.2. Rising Prevalence of Chronic and Neurodegenerative Diseases
    • 3.2.1.3. Advancements in Ultrasensitive Immunoassay Technologies
    • 3.2.1.4. Increasing Adoption of Automated High-Throughput Immunoassay Platforms
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. High Cost of Advanced Protein Biomarker Immunoassays
    • 3.2.2.2. Complexity of Biomarker Validation and Standardization
  • 3.2.3. Market opportunity analysis
• 3.3. Global Protein Biomarker Immunoassay Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
  • 3.3.2. PESTLE Analysis

Chapter 4. Global Protein Biomarker Immunoassay Market: Product Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Global Protein Biomarker Immunoassay Market Product Movement Analysis
• 4.3. Global Protein Biomarker Immunoassay Market Size & Trend Analysis, by Product, 2021 to 2033 (USD Billion)
• 4.4. Reagents & Consumables
  • 4.4.1. Reagents & Consumables market estimates and forecasts 2021 to 2033 (USD Billion)
• 4.5. Instruments
  • 4.5.1. Instruments market estimates and forecasts 2021 to 2033 (USD Billion)
• 4.6. Software & Services
  • 4.6.1. Software & Services market estimates and forecasts 2021 to 2033 (USD Billion)

Chapter 5. Global Protein Biomarker Immunoassay Market: Technology Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Global Protein Biomarker Immunoassay Market Technology Movement Analysis
  • 5.2.1. Global Protein Biomarker Immunoassay Market Size & Trend Analysis, by Technology, 2021 to 2033 (USD Billion)
• 5.3. Chemiluminescence Immunoassay
  • 5.3.1. Chemiluminescence Immunoassay market estimates and forecasts 2021 to 2033 (USD Billion)
• 5.4. ELISA
  • 5.4.1. ELISA market estimates and forecasts 2021 to 2033 (USD Billion)
• 5.5. Fluorescence Immunoassay
  • 5.5.1. Fluorescence Immunoassay market estimates and forecasts 2021 to 2033 (USD Billion)
• 5.6. Immunoturbidimetry & Nephelometry
  • 5.6.1. Immunoturbidimetry & Nephelometry market estimates and forecasts 2021 to 2033 (USD Billion)
• 5.7. Lateral Flow Immunoassay
  • 5.7.1. Lateral Flow Immunoassay market estimates and forecasts 2021 to 2033 (USD Billion)
• 5.8. Multiplex Immunoassay
  • 5.8.1. Multiplex Immunoassay market estimates and forecasts 2021 to 2033 (USD Billion)
• 5.9. Digital Immunoassay
  • 5.9.1. Digital Immunoassay market estimates and forecasts 2021 to 2033 (USD Billion)
• 5.10. Others
  • 5.10.1. Others market estimates and forecasts 2021 to 2033 (USD Billion)

Chapter 6. Global Protein Biomarker Immunoassay Market: Clinical Application Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Global Protein Biomarker Immunoassay Market Clinical Application Movement Analysis
  • 6.2.1. Global AI-enabled clinical laboratory analyzer Market Size & Trend Analysis, by Clinical Application, 2021 to 2033 (USD Billion)
• 6.3. Cardiology
  • 6.3.1. Cardiology market estimates and forecasts 2021 to 2033 (USD Billion)
• 6.4. Oncology
  • 6.4.1. Oncology market estimates and forecasts 2021 to 2033 (USD Billion)
• 6.5. Infectious Disease & Inflammation
  • 6.5.1. Infectious Disease & Inflammation market estimates and forecasts 2021 to 2033 (USD Billion)
• 6.6. Neurology
• 6.7. Neurology market estimates and forecasts 2021 to 2033 (USD Billion)
• 6.8. Endocrine & Metabolic Disorders
  • 6.8.1. Endocrine & Metabolic Disorders market estimates and forecasts 2021 to 2033 (USD Billion)
• 6.9. Women's Health & Reproductive Disorders
  • 6.9.1. Women's Health & Reproductive Disorders market estimates and forecasts 2021 to 2033 (USD Billion)
• 6.10. Autoimmune & Allergy Disorders
  • 6.10.1. Autoimmune & Allergy Disorders market estimates and forecasts 2021 to 2033 (USD Billion)
• 6.11. Renal Disorders
  • 6.11.1. Renal Disorders market estimates and forecasts 2021 to 2033 (USD Billion)
• 6.12. Others
  • 6.12.1. Others market estimates and forecasts 2021 to 2033 (USD Billion)

Chapter 7. Global Protein Biomarker Immunoassay Market: Sample Estimates & Trend Analysis

• 7.1. Segment Dashboard
• 7.2. Global Protein Biomarker Immunoassay Market Sample Movement Analysis
  • 7.2.1. Global AI-enabled clinical laboratory analyzer Market Size & Trend Analysis, by Sample, 2021 to 2033 (USD Billion)
• 7.3. Serum
  • 7.3.1. Serum market estimates and forecasts 2021 to 2033 (USD Billion)
• 7.4. Plasma
  • 7.4.1. Plasma market estimates and forecasts 2021 to 2033 (USD Billion)
• 7.5. Whole Blood
  • 7.5.1. Whole Blood market estimates and forecasts 2021 to 2033 (USD Billion)
• 7.6. Urine
• 7.7. Urine market estimates and forecasts 2021 to 2033 (USD Billion)
• 7.8. Cerebrospinal Fluid
  • 7.8.1. Cerebrospinal Fluid market estimates and forecasts 2021 to 2033 (USD Billion)
• 7.9. Saliva
  • 7.9.1. Saliva market estimates and forecasts 2021 to 2033 (USD Billion)
• 7.10. Others
  • 7.10.1. Others market estimates and forecasts 2021 to 2033 (USD Billion)

Chapter 8. Global Protein Biomarker Immunoassay Market: End User Estimates & Trend Analysis

• 8.1. Segment Dashboard
• 8.2. Global Protein Biomarker Immunoassay Market End User Movement Analysis
  • 8.2.1. Global AI-enabled clinical laboratory analyzer Market Size & Trend Analysis, by End User, 2021 to 2033 (USD Billion)
• 8.3. Hospitals & Clinics
  • 8.3.1. Hospitals & Clinics market estimates and forecasts 2021 to 2033 (USD Billion)
• 8.4. Diagnostic Laboratories
  • 8.4.1. Diagnostic Laboratories market estimates and forecasts 2021 to 2033 (USD Billion)
• 8.5. Academic Medical Centers
  • 8.5.1. Academic Medical Centers market estimates and forecasts 2021 to 2033 (USD Billion)
• 8.6. Specialty Diagnostic Centers
• 8.7. Specialty Diagnostic Centers market estimates and forecasts 2021 to 2033 (USD Billion)
• 8.8. Others
  • 8.8.1. Others market estimates and forecasts 2021 to 2033 (USD Billion)

Chapter 9. Protein Biomarker Immunoassay Market: Regional Estimates & Trend Analysis

• 9.1. Regional Dashboard
• 9.2. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
• 9.3. North America
  • 9.3.1. U.S.
    • 9.3.1.1. Key country dynamics
    • 9.3.1.2. Regulatory framework/ reimbursement structure
    • 9.3.1.3. Competitive scenario
    • 9.3.1.4. U.S. market estimates and forecasts 2021 to 2033 (USD Billion)
  • 9.3.2. Canada
    • 9.3.2.1. Key country dynamics
    • 9.3.2.2. Regulatory framework/ reimbursement structure
    • 9.3.2.3. Competitive scenario
    • 9.3.2.4. Canada market estimates and forecasts 2021 to 2033 (USD Billion)
  • 9.3.3. Mexico
    • 9.3.3.1. Key country dynamics
    • 9.3.3.2. Regulatory framework/ reimbursement structure
    • 9.3.3.3. Competitive scenario
    • 9.3.3.4. Mexico market estimates and forecasts 2021 to 2033 (USD Billion)
• 9.4. Europe
  • 9.4.1. UK
    • 9.4.1.1. Key country dynamics
    • 9.4.1.2. Regulatory framework/ reimbursement structure
    • 9.4.1.3. Competitive scenario
    • 9.4.1.4. UK market estimates and forecasts 2021 to 2033 (USD Billion)
  • 9.4.2. Germany
    • 9.4.2.1. Key country dynamics
    • 9.4.2.2. Regulatory framework/ reimbursement structure
    • 9.4.2.3. Competitive scenario
    • 9.4.2.4. Germany market estimates and forecasts 2021 to 2033 (USD Billion)
  • 9.4.3. France
    • 9.4.3.1. Key country dynamics
    • 9.4.3.2. Regulatory framework/ reimbursement structure
    • 9.4.3.3. Competitive scenario
    • 9.4.3.4. France market estimates and forecasts 2021 to 2033 (USD Billion)
  • 9.4.4. Italy
    • 9.4.4.1. Key country dynamics
    • 9.4.4.2. Regulatory framework/ reimbursement structure
    • 9.4.4.3. Competitive scenario
    • 9.4.4.4. Italy market estimates and forecasts 2021 to 2033 (USD Billion)
  • 9.4.5. Spain
    • 9.4.5.1. Key country dynamics
    • 9.4.5.2. Regulatory framework/ reimbursement structure
    • 9.4.5.3. Competitive scenario
    • 9.4.5.4. Spain market estimates and forecasts 2021 to 2033 (USD Billion)
  • 9.4.6. Norway
    • 9.4.6.1. Key country dynamics
    • 9.4.6.2. Regulatory framework/ reimbursement structure
    • 9.4.6.3. Competitive scenario
    • 9.4.6.4. Norway market estimates and forecasts 2021 to 2033 (USD Billion)
  • 9.4.7. Sweden
    • 9.4.7.1. Key country dynamics
    • 9.4.7.2. Regulatory framework/ reimbursement structure
    • 9.4.7.3. Competitive scenario
    • 9.4.7.4. Sweden market estimates and forecasts 2021 to 2033 (USD Billion)
  • 9.4.8. Denmark
    • 9.4.8.1. Key country dynamics
    • 9.4.8.2. Regulatory framework/ reimbursement structure
    • 9.4.8.3. Competitive scenario
    • 9.4.8.4. Denmark market estimates and forecasts 2021 to 2033 (USD Billion)
• 9.5. Asia Pacific
  • 9.5.1. Japan
    • 9.5.1.1. Key country dynamics
    • 9.5.1.2. Regulatory framework/ reimbursement structure
    • 9.5.1.3. Competitive scenario
    • 9.5.1.4. Japan market estimates and forecasts 2021 to 2033 (USD Billion)
  • 9.5.2. China
    • 9.5.2.1. Key country dynamics
    • 9.5.2.2. Regulatory framework/ reimbursement structure
    • 9.5.2.3. Competitive scenario
    • 9.5.2.4. China market estimates and forecasts 2021 to 2033 (USD Billion)
  • 9.5.3. India
    • 9.5.3.1. Key country dynamics
    • 9.5.3.2. Regulatory framework/ reimbursement structure
    • 9.5.3.3. Competitive scenario
    • 9.5.3.4. India market estimates and forecasts 2021 to 2033 (USD Billion)
  • 9.5.4. Australia
    • 9.5.4.1. Key country dynamics
    • 9.5.4.2. Regulatory framework/ reimbursement structure
    • 9.5.4.3. Competitive scenario
    • 9.5.4.4. Australia market estimates and forecasts 2021 to 2033 (USD Billion)
  • 9.5.5. South Korea
    • 9.5.5.1. Key country dynamics
    • 9.5.5.2. Regulatory framework/ reimbursement structure
    • 9.5.5.3. Competitive scenario
    • 9.5.5.4. South Korea market estimates and forecasts 2021 to 2033 (USD Billion)
  • 9.5.6. Thailand
    • 9.5.6.1. Key country dynamics
    • 9.5.6.2. Regulatory framework/ reimbursement structure
    • 9.5.6.3. Competitive scenario
    • 9.5.6.4. Thailand market estimates and forecasts 2021 to 2033 (USD Billion)
• 9.6. Latin America
  • 9.6.1. Brazil
    • 9.6.1.1. Key country dynamics
    • 9.6.1.2. Regulatory framework/ reimbursement structure
    • 9.6.1.3. Competitive scenario
    • 9.6.1.4. Brazil market estimates and forecasts 2021 to 2033 (USD Billion)
  • 9.6.2. Argentina
    • 9.6.2.1. Key country dynamics
    • 9.6.2.2. Regulatory framework/ reimbursement structure
    • 9.6.2.3. Competitive scenario
    • 9.6.2.4. Argentina market estimates and forecasts 2021 to 2033 (USD Billion)
• 9.7. MEA
  • 9.7.1. South Africa
    • 9.7.1.1. Key country dynamics
    • 9.7.1.2. Regulatory framework/ reimbursement structure
    • 9.7.1.3. Competitive scenario
    • 9.7.1.4. South Africa market estimates and forecasts 2021 to 2033 (USD Billion)
  • 9.7.2. Saudi Arabia
    • 9.7.2.1. Key country dynamics
    • 9.7.2.2. Regulatory framework/ reimbursement structure
    • 9.7.2.3. Competitive scenario
    • 9.7.2.4. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Billion)
  • 9.7.3. UAE
    • 9.7.3.1. Key country dynamics
    • 9.7.3.2. Regulatory framework/ reimbursement structure
    • 9.7.3.3. Competitive scenario
    • 9.7.3.4. UAE market estimates and forecasts 2021 to 2033 (USD Billion)
  • 9.7.4. Kuwait
    • 9.7.4.1. Key country dynamics
    • 9.7.4.2. Regulatory framework/ reimbursement structure
    • 9.7.4.3. Competitive scenario
    • 9.7.4.4. Kuwait market estimates and forecasts 2021 to 2033 (USD Billion)

Chapter 10. Competitive Landscape

• 10.1. Company/Competition Categorization
• 10.2. Strategy Mapping
• 10.3. Company Market Share Analysis, 2025
• 10.4. List of Key Certification Providers/Scheme Owners
• 10.5. Company Profiles/Listing
  • 10.5.1. Siemens Healthineers AG
    • 10.5.1.1. Company overview
    • 10.5.1.2. Financial performance
    • 10.5.1.3. Product benchmarking
    • 10.5.1.4. Strategic initiatives
  • 10.5.2. Beckman Coulter, Inc.
    • 10.5.2.1. Company overview
    • 10.5.2.2. Financial performance
    • 10.5.2.3. Product benchmarking
    • 10.5.2.4. Strategic initiatives
  • 10.5.3. QuidelOrtho Corporation.
    • 10.5.3.1. Company overview
    • 10.5.3.2. Financial performance
    • 10.5.3.3. Product benchmarking
    • 10.5.3.4. Strategic initiatives
  • 10.5.4. BIOMERIEUX
    • 10.5.4.1. Company overview
    • 10.5.4.2. Financial performance
    • 10.5.4.3. Product benchmarking
    • 10.5.4.4. Strategic initiatives
  • 10.5.5. Tosoh Bioscience, Inc.
    • 10.5.5.1. Company overview
    • 10.5.5.2. Financial performance
    • 10.5.5.3. Product benchmarking
    • 10.5.5.4. Strategic initiatives
  • 10.5.6. Fujirebio
    • 10.5.6.1. Company overview
    • 10.5.6.2. Financial performance
    • 10.5.6.3. Product benchmarking
    • 10.5.6.4. Strategic initiatives
  • 10.5.7. DiaSorin S.p.A.
    • 10.5.7.1. Company overview
    • 10.5.7.2. Financial performance
    • 10.5.7.3. Product benchmarking
    • 10.5.7.4. Strategic initiatives
  • 10.5.8. Thermo Fisher Scientific Inc.
    • 10.5.8.1. Company overview
    • 10.5.8.2. Financial performance
    • 10.5.8.3. Product benchmarking
    • 10.5.8.4. Strategic initiatives
  • 10.5.9. F. Hoffmann-La Roche Ltd.
    • 10.5.9.1. Company overview
    • 10.5.9.2. Financial performance
    • 10.5.9.3. Product benchmarking
    • 10.5.9.4. Strategic initiatives
  • 10.5.10. Abbott.
    • 10.5.10.1. Company overview
    • 10.5.10.2. Financial performance
    • 10.5.10.3. Product benchmarking
    • 10.5.10.4. Strategic initiatives